Systemic mastocytosis in association with chronic lymphocytic leukemia: A rare diagnosis

Leukemia Research

Volumn 31, Issue 12, 2007, Pages 1755-1758

  Ault, Patricia ^a   Lynn, Alice ^a   Tam, Constantine S ^a   Medeiros, L Jeffrey ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alemtuzumab; Imatinib; Lymphoproliferative diseases; Myeloproliferative disease

Indexed keywords

ALEMTUZUMAB; CYCLOPHOSPHAMIDE; FLUDARABINE; IMATINIB; RITUXIMAB;

ADULT; ANAMNESIS; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; DISEASE ASSOCIATION; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LYMPHOCYTOSIS; MALE; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TREATMENT RESPONSE; VERTEBRA FRACTURE;

BONE MARROW EXAMINATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY;

EID: 35648961030     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.04.002     Document Type: Article

References (20)

1. Jaffe E.S., Harris N.L., Stein H., and Vardiman J.W. World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon
2. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25 (2001) 603-625
3. Wolff K., Komar M., and Petzelbauer P. Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 25 (2001) 519-528
4. Horny H.P., Sotlar K., Sperr W.R., and Valent P. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 57 (2004) 604-608
5. Tournilhac O., Santos D.D., Xu L., et al. Mast cells in Waldenstrom's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol 17 (2006) 1275-1282
6. Santos D.D., Hatjiharissi E., Tournilhac O., et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 6 (2006) 478-483
7. Dighiero G., and Binet J.L. When and how to treat chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1799-1801
8. Horny H.P., Sotlar K., Stellmacher F., Valent P., and Grabbe J. An unusual case of systemic mastocytosis associated with chronic lymphocytic leukaemia (SM-CLL). J Clin Pathol 59 (2006) 264-268
9. Sanz M.A., Valcarcel D., Sureda A., et al. Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica 86 (2001) 1106-1107
10. Droogendijk H.J., Kluin-Nelemans H.J., van Doormaal J.J., Oranje A.P., van de Loosdrecht A.A., and van Daele P.L. Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial. Cancer 107 (2006) 345-351
11. Dohner H., Stilgenbauer S., Benner A., et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1910-1916
12. Rassenti L.Z., Huynh L., Toy T.L., et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351 (2004) 893-901
13. Wierda WG, O'Brien S, Ferrajoli A, et al. Salvage therapy with combined cyclophosphamide (c), fludarabine (f), alemtuzumab (a), and rituximab (r) (cfar) for heavily pre-treated patients with CLL. ASH Annual Meeting Abstracts 2005;106:719.
14. Escribano L., Diaz-Agustin B., Nunez R., Prados A., Rodriguez R., and Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 127 (2002) 127-132
15. Tefferi A., and Pardanani A. Clinical, genetic, and therapeutic insights into systemic mast cell disease. Curr Opin Hematol 11 (2004) 58-64
16. Akin C., and Metcalfe D.D. Surrogate markers of disease in mastocytosis. Int Arch Allergy Immunol 127 (2002) 133-136
17. Kushnir-Sukhov N.M., Brittain E., Reynolds J.C., Akin C., and Metcalfe D.D. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 139 (2006) 265-270
18. Schwartz L.B. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 25 (2001) 553-562
19. Kanakura Y., Furitsu T., Tsujimura T., et al. Activating mutations of the c-kit proto-oncogene in a human mast cell leukemia cell line. Leukemia 8 Suppl. 1 (1994) S18-S22
20. Elter T., Borshmann P., Schulz H., et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 23 (2005) 7024-7031